Highest-materiality recent filing
TuHURA Biosciences draws $1.7M from $50M revolving credit facility
First draw of $1.7M under $50M revolving credit facility with Parkview Holdings One LLC.
TuHURA Q1 cash $6.3M; secures $50M credit facility; IFx-2.0 gets ODD in melanoma
Cash and equivalents $6.3M at March 31, 2026; net operating cash outflow $4.4M in Q1.
TuHURA corrects pro forma financials for Kineta merger; FY2025 net loss $34.6M
Corrected unaudited pro forma combined net loss for FY2025: $34.5M ($34.6M attributable to common), EPS -$0.66.
$50M revolving credit facility from Parkview (affiliate of largest stockholder) at 12% interest, matures April 2031.
TuHURA pro forma 2025 net loss $34.6M after Kineta acquisition; exec bonuses approved
Pro forma net loss attributable to common stockholders $34.57M, or $(0.64) per share, for year ended Dec 31, 2025.
TuHURA FY2025 cash $3.6M, R&D $20.5M; Phase 3 MCC trial ongoing; Kineta acquired
Cash $3.6M at Dec 31, 2025; additional $7.5M from 2025 registered direct offering received Q1 2026.
Nasdaq letter on Jan 29, 2026, for bid price <$1.00 for 35 consecutive days, violating Listing Rule 5550(a)(2).
TuHURA Biosciences prices $15.6M registered direct offering of stock and warrants in three tranches
TuHURA prices registered direct offering of 9.46M shares and Series A/B warrants at $1.65/unit; warrants exercisable at $1.95 after six months.
TuHURA draws additional $1.5M under amended loan; total $3M, issues warrants
Borrowed an additional $1.5M on Dec 2, 2025, bringing aggregate loans to $3.0M under the Loan Agreement.
TuHURA Biosciences S-3 shelf registration becomes effective; resale S-1 terminated
S-3 registration statement (File No. 333-291239) declared effective by SEC on November 22, 2025.
TuHURA provides pro forma statements for Kineta merger, closed June 30, 2025
Pro forma combined statements for nine months ended Sept 30, 2025 and year ended Dec 31, 2024.
TuHURA reports Q3 R&D $4.9M, cash burn $22.1M; Phase 3 MCC trial underway
Phase 3 IFx-2.0 trial for MCC under SPA enrollment ongoing; topline results expected Q1 2027.
TuHURA Biosciences enters ATM agreement for up to $50M in common stock sales
Up to $50M of common stock may be sold through H.C. Wainwright as sales agent.
TuHURA starts Phase 3 IFx-2.0 trial, acquires TBS-2025, defers IFx-3.0
Initiated Phase 3 trial of IFx-2.0 + Keytruda in 1L Merkel cell carcinoma under FDA SPA for accelerated approval.
TuHURA secures $3M bridge loan at 3% monthly interest, secured by ImmuneFx patents
Initial $1.5M advance from Matthew Nachtrab Revocable Trust on Oct 27, 2025; up to $3M total available.
TuHURA closes $3.2M final tranche; extends 2024 warrants for 1.5M shares to 2030
Deferred investors purchased $3.2M of final tranche on Sept 5, 2025, accelerating ~80% of the remaining $3.7M offering.
TuHURA Q2 R&D $4.9M, initiates Phase 3 IFx-2.0 trial, acquires Kineta VISTA mAb
Completed acquisition of Kineta; VISTA mAb (TBS-2025) Phase 2 AML trial planned for 2H 2025.
Kineta acquisition closed; Q1 2025 financials show $1.7M net loss and $13.2M deficit
Cash $304K, total liabilities $14M, stockholders' deficit $13.2M as of March 31, 2025.
TuHURA completes Kineta acquisition, adds Phase 2 VISTA mAb TBS-2025
Each Kineta share converted into 0.185298 TuHURA shares; ~2.87M shares issued at closing, plus up to ~1.13M additional shares subject to six-month adjustment.
TuHURA Biosciences increases authorized common shares from 75M to 200M
Stockholders approved amendment at June 23, 2025 special meeting.
TuHURA and Kineta stockholders approve merger; authorized shares increased to 200M
TuHURA shareholders approved all proposals: authorized shares increased from 75M to 200M, reincorporation to Delaware.
TuHURA raises CEO salary to $577K, CFO to $384K; approves 2024 bonuses
CEO James Bianco base salary increased to $577,101; CFO Dan Dearborn to $384,453 effective June 6, 2025.
TuHURA raises $12.6M in private placement, $3M from warrants, tied to Phase 3 & merger milestones
Total offering $12.6M (4.76M shares + warrants at $2.65/unit). Initial closing $2.23M.
TuHURA Q1 expenses rise; Phase 3 MCC trial and Kineta merger on track for Q2 2025
Q1 2025 R&D expenses $4.6M (up 28% YoY); G&A $2.4M (up 140% YoY); shares outstanding ~43.7M.
Board appointed Dr. Craig Tendler to the Nominating and Corporate Governance Committee effective May 5, 2025.
TuHURA amends Kineta merger; revises consideration, extends end date to June 30, 2025
First Amendment revises merger consideration: Initial Stock Consideration based on $16.5M less adjustments at $5.7528/share.
TuHURA reports FY2024 R&D $13.3M, cash through late Q4 2025; Phase 3 trial to start Q2
Full-year 2024 R&D expense $13.3M (up from $9.4M); G&A $4.3M (vs $4.1M prior year).
TuHURA furnishes investor presentation; merger with Kineta ongoing
Investor presentation used for meetings with investors and analysts starting March 18, 2025.
TuHURA appoints Dr. Craig Tendler (ex-J&J oncology VP) to Board, effective March 10, 2025
Dr. Tendler oversaw 30 major oncology drug approvals at J&J, including DARZALEX, ZYTIGA, and BALVERSA.
TuHURA receives $3.0M in secured notes from warrant holders for 1.03M shares
Aggregate $3,011,372.60 in secured promissory notes from four Makers, including KP Biotech Group, CA Patel F&F, Kiran C. Patel, and Donald Wojnowski.
TuHURA dismisses Marcum as auditor, appoints Cherry Bekaert after merger
Marcum dismissed as independent auditor effective Dec 31, 2024; Audit Committee approved Dec 27, 2024.
TuHURA to acquire Kineta in stock/cash merger; $35M concurrent financing required
Consideration per Kineta share: initial stock based on $15M pool, delayed stock based on $5M, plus cash and contingent asset payment rights.
TuHURA plans IFx-2.0 Phase 3 trial under SPA; signs non-binding LOI to acquire Kineta's KVA12123
IFx-2.0 Phase 3 accelerated approval trial in first-line MCC to start H1 2025 under FDA SPA, with ORR primary and PFS secondary endpoints.
TuHURA raises CEO & CFO base salaries; grants options for 1.56M shares at $4.94
CEO Bianco base salary increased to $499,000; CFO Dearborn to $375,000, effective Jan 1, 2025.
TuHURA posts $15.7M net loss through Q3 2024; convertible debt rises to $24.4M
Net loss of $15.7M for nine months ended Sep 30, 2024 vs $26.6M prior year (prior year included $16.2M IPR&D charge).
Kintara completes reverse merger with TuHURA; renamed TuHURA Biosciences, trades as HURA
Merger closed Oct 18, 2024; Kintara securityholders own ~2.85% of combined entity (or 5.45% if CVR milestone met).
Kintara sets Oct 17 record date for CVRs; TuHURA merger expected Oct 18
Record date of Oct 17, 2024 for CVR issuance to Kintara stockholders.
Kintara retracts Oct 17 CVR record date; CVRs to pre-reverse-split holders ahead of Oct 18 merger
CVRs will be issued to stockholders of record immediately prior to the 1-for-35 reverse split, not on Oct 17 as previously announced.
Kintara stockholders approve TuHURA merger; FY2024 net loss $8.32M
Stockholders approved merger with TuHURA on Oct 4, 2024; closing expected mid-October 2024.
TuHURA reports H1 2024 net loss $10.1M, cash $12.3M; merger with Kintara on track for Q4 2024
Net loss $10.1M for six months ended June 30, 2024; prior period loss $22.1M incl $16.2M IPR&D charge.
Kintara shareholders approve merger proposals; charter increase and reincorporation fail
Nasdaq Proposal to approve merger share issuance passed: 26.75M for, 1.18M against.
TuHURA waives requirement for Kintara stockholder vote on reincorporation from Nevada to Delaware.
Kintara adjourns special meeting; merger vote faces shortfall, adjourned to Oct 4
Special meeting adjourned to Oct 4, 2024 at 9:00 am EST; voting threshold not reached for Proposals 3 & 5.
Kintara adjourns special meeting to Oct 4 due to insufficient votes on merger-related proposals
Special Meeting on Sept 20, 2024 adjourned to Oct 4, 2024 because insufficient votes on Proposal 3 (increase authorized shares to 400M) and Proposal 5 (reincorporation to Delaware).
Kintara and TuHURA post on social media urging vote on merger at Special Meeting
Posts on LinkedIn and X on Sep 18, 2024, regarding Kintara's Special Meeting for the proposed merger with TuHURA.
Kintara says merger vote threshold not yet met; stockholders urged to vote by Sept 19
Special meeting on Sept 20; votes must be cast by 11:59pm ET Sept 19 to count.
Special Meeting on Sept 20, 2024 to vote on TuHURA merger; existing holders get 5.45% of combined co. plus CVRs.
Kintara warns of possible bankruptcy if TuHURA merger fails; special meeting Sept 20
Special meeting to approve merger with TuHURA set for Sept 20, 2024; vote deadline Sept 19 at 11:59 p.m. ET.
Kintara warns stockholder vote failure could lead to bankruptcy, delisting
Voting deadline for merger with TuHURA is Sept 19, 2024 at 11:59 p.m. ET; special meeting Sept 20.
Kineta reopens VISTA-101 trial; 30 of 39 patients enrolled; KVA12123 safe
Kineta reopened enrollment in VISTA-101 Phase 1/2 trial for KVA12123; expects full enrollment by end of 2024.
the Separation Agreement confirms that Mr. Yamashita’s employment with TuHURA terminated effective December 16, 2024
On March 7, 2025, the Board of Directors (the “Board”) of TuHURA Biosciences, Inc. (the “Company”) increased the size of the Board from five members to six members and appointed Dr. Craig Tendler to the Board, effective as of March 10, 2025, to serve as a director until the Company’s 2025 Annual Meeting of Stockholders and until his successor has been duly elected and qualified or until his earlier death, resignation or removal.
Max materiality 1.00 · Median 0.62 · Most common event other_material